Get started
Author

Margherita Rimini

Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population
2022 · Andrea Casadei-Gardini, Margherita Rimini, et al. · European Journal of Cancer · 131
PDF
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study
2023 · Qinghe Zeng, Christophe Klein, et al. · The Lancet Oncology · 129
PDF
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis
2022 · M. Rimini, L. Rimassa, et al. · ESMO Open · 127
PDF
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data
2023 · Margherita Rimini, Lorenzo Fornaro, et al. · Liver International · 114
PDF
Lenvatinib versus sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis
2021 · Andrea Casadei‐Gardini, Mario Scartozzi, et al. · Liver International · 61
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population
2024 · Margherita Rimini, Lorenzo Fornaro, et al. · European Journal of Cancer · 59
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients
2023 · Mara Persano, Margherita Rimini, et al. · European Journal of Cancer · 58
PDF
Clinical Implications of Malnutrition in the Management of Patients with Pancreatic Cancer: Introducing the Concept of the Nutritional Oncology Board
2021 · Giulia Rovesti, Filippo Valoriani, et al. · Nutrients · 58
PDF
Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study
2021 · Margherita Rimini, Shigeo Shimose, et al. · Hepatology Research · 46
PDF
Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib
2021 · M. Rimini, M. Kudo, et al. · ESMO Open · 45
PDF
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients
2023 · Margherita Rimini, Mara Persano, et al. · Journal of Cancer Research and Clinical Oncology · 42
PDF
Lenvatinib as a therapy for unresectable hepatocellular carcinoma
2018 · Andrea Spallanzani, Giulia Orsi, et al. · Expert Review of Anticancer Therapy · 40
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study
2022 · Andrea Casadei-Gardini, Margherita Rimini, et al. · Liver Cancer · 39
PDF
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy
2021 · Valentina Burgio, Massimo Iavarone, et al. · Cancer Management and Research · 39
PDF
Effect of the combination of clarithromycin and amikacin on Pseudomonas aeruginosa biofilm in an animal model of ureteral stent infection
2011 · O. Cirioni, R. Ghiselli, et al. · Journal of Antimicrobial Chemotherapy · 39
Cholangiocarcinoma: new perspectives for new horizons
2021 · Margherita Rimini, Marco Puzzoni, et al. · Expert Review of Gastroenterology & Hepatology · 34
The beneficial impact of metabolic dysfunction‐associated fatty liver disease on lenvatinib treatment in patients with non‐viral hepatocellular carcinoma
2022 · Shigeo Shimose, Atsushi Hiraoka, et al. · Hepatology Research · 31
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study
2024 · Federico Rossari, Toshifumi Tada, et al. · Liver Cancer · 30
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study
2022 · Mara Persano, Margherita Rimini, et al. · Journal of Cancer Research and Clinical Oncology · 30
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study
2024 · Margherita Rimini, Gianluca Masi, et al. · Targeted Oncology · 27
PDF
The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy
2019 · Massimiliano Salati, Francesco Caputo, et al. · European Journal of Cancer · 27
PDF
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab
2023 · Mara Persano, Margherita Rimini, et al. · Oncology · 26
PDF
Could Inflammatory Indices and Metabolic Syndrome Predict the Risk of Cancer Development? Analysis from the Bagnacavallo Population Study
2020 · Margherita Rimini, Andrea Casadei-Gardini, et al. · Journal of Clinical Medicine · 26
PDF
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies
2024 · Alessandro Parisi, Blandine Delaunay, et al. · European Journal of Cancer · 25
PDF
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib
2021 · Ilario Giovanni Rapposelli, Toshifumi Tada, et al. · Liver International · 24
Works count: 163
Citation count: 1,982
H-index: 24
I10-index: 56
Year
Topic
Type